细菌多糖结合疫苗的研究进展  

Recent progress in the field of bacterial polysaccharide conjugate vaccines

作　　者：邓国英[1] 桑彤 杨淑凤[1] DENG Guo-Ying;SANG Tong;YANG Shu-Feng(Department of Microbiology,Dalian Medical University,Dalian 116044,China;Dalian Medical University,Dalian 116044,China)

机构地区：[1]大连医科大学微生物学教研室,大连116044 [2]大连医科大学,大连116044

出　　处：《生命科学》2022年第1期39-44,共6页Chinese Bulletin of Life Sciences

基　　金：国家自然科学基金项目(81801981)。

摘　　要：多糖结合疫苗(glycoconjugate vaccines)是指具有可变结构和数量的多糖单元与非糖单元(蛋白质或短肽、脂类)通过共价连接形成的疫苗,以蛋白质-多糖结合疫苗为主。细菌的多糖结合疫苗通过直接免疫保护和群体免疫,显著减低了由细菌侵袭性感染所致的肺炎和脑膜炎的发病率和病死率。该文从组成和免疫机制、合成方法和面临的问题等方面重点论述了已上市的以及正处于临床试验阶段的几种细菌蛋白多糖疫苗,对细菌多糖结合疫苗的全面认识有助于设计更为合理的疫苗。Glycoconjugate vaccines are the compounds which consist of carbohydrates of varying complexity and size, covalently linked to non-sugar moieties such as proteins, peptides, and lipids. Bacterial polysaccharide conjugate vaccines have markedly decreased the global morbidity and mortality caused by bacterial meningitis and pneumonia, through direct immuno-protection and herd immunity. This review focuses on compositions,vaccine-induced immunity, synthetic methods, and characteristics of the several bacterial polysaccharide conjugate vaccines including licensed and being on trial.

关 键 词：疫苗 糖结合疫苗 荚膜多糖 侵袭性感染 群体免疫 

分 类 号：R392[医药卫生—免疫学]